• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

    0.5696 +0.0099 (+1.77%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 749,358
    Open 0.5600
    Bid (Size) 0.5700 (55)
    Ask (Size) 0.5789 (50)
    Prev. Close 0.5597
    Today's Range 0.5532 - 0.5800
    52wk Range 0.3418 - 1.830
    Shares Outstanding 85,029,042
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -45.2%
    -45.2%
    1 Month
    +14.6%
    +14.6%
    3 Month
    -1.5%
    -1.5%
    6 Month
    +13.7%
    +13.7%
    1 Year
    -61.5%
    -61.5%

    More News

    Read More
    Century Reports Flat Loss in Fiscal Q2
    Via The Motley Fool
    4 Analysts Have This To Say About Century Therapeutics
    Via Benzinga
    Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Monday's after hours session: top gainers and losers
    Via Chartmill
    Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    Demystifying Century Therapeutics: Insights From 4 Analyst Reviews
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
    Via Benzinga
    Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga

    Frequently Asked Questions

    Is Century Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Century Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Century Therapeutics, Inc. - Common Stock trade on?
    Century Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Century Therapeutics, Inc. - Common Stock?
    The ticker symbol for Century Therapeutics, Inc. - Common Stock is IPSC on the Nasdaq Stock Market
    What is the current price of Century Therapeutics, Inc. - Common Stock?
    The current price of Century Therapeutics, Inc. - Common Stock is 0.5696
    When was Century Therapeutics, Inc. - Common Stock last traded?
    The last trade of Century Therapeutics, Inc. - Common Stock was at 10/15/25 04:00 PM ET
    What is the market capitalization of Century Therapeutics, Inc. - Common Stock?
    The market capitalization of Century Therapeutics, Inc. - Common Stock is 48.43M
    How many shares of Century Therapeutics, Inc. - Common Stock are outstanding?
    Century Therapeutics, Inc. - Common Stock has 48M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.